深圳微芯生物科技股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported significant growth in its 2025 annual performance, with notable increases in revenue and net profit, driven by successful commercialization of its products and strategic partnerships [3][4]. Financial Data Summary - The company's 2025 annual operating revenue reached 909.54 million yuan, with a total profit of 50.84 million yuan and a net profit attributable to shareholders of 51.08 million yuan [3]. - The net profit after deducting non-recurring gains and losses was 38.36 million yuan, and the earnings per share stood at 0.1252 yuan [3]. Performance Drivers - The product Siglepag's unique clinical value contributed to a significant sales revenue increase of approximately 122% year-on-year, supported by self-operated channels, strategic partnerships, and new retail initiatives [4]. - The product Sidaben's clinical value received recognition from the National Medical Insurance Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory, leading to a sales revenue increase of about 16% year-on-year [4]. Growth Metrics - The company's total operating revenue grew by 38.24%, with operating profit, total profit, net profit attributable to shareholders, net profit after deducting non-recurring gains and losses, and basic earnings per share increasing by 128.52%, 152.57%, 144.58%, 118.69%, and 144.59% respectively [5].